A Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel Group, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Abilify Tablet(Aripiprazole) as an Adjunctive Treatment in the Treatment of Major Depressive Episode Associated With Bipolar I or II Disorder
Phase of Trial: Phase III
Latest Information Update: 11 Jan 2019
Price : $35 *
At a glance
- Drugs Aripiprazole (Primary)
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- Acronyms APOLLO
- Sponsors Korea Otsuka Pharmaceutical
- 04 Jan 2019 Planned End Date changed from 1 Feb 2022 to 1 Jun 2020.
- 04 Jan 2019 Planned primary completion date changed from 1 Jul 2021 to 1 Mar 2020.
- 05 Mar 2018 Status changed from not yet recruiting to recruiting.